Developer docs
API playgroundTry for free, no card

Search company profiles

Richen Europe

Full company profile

uuid000wdiq

Namestring
Richen Europe
Legal namestring
Richen Europe S.r.l.
Websiteurl
richeneurope.eu
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Richen Europe S.r.l. is an Italian pharmaceutical company founded in 2014 and headquartered in Trezzano Sul Naviglio (Milan), operating as the European subsidiary of the Richen Medical Science Group, whose Chinese parent is Beijing Richen Force Science & Technology Co., Ltd. The company manufactures medical diagnostic products and medical instrumentation focused on gastroenterology, serving hospitals, clinical laboratories, and gastroenterology departments across European markets with a stated base of approximately 285 international clients and 13 gastroenterology products. The group is led by Managing Director Dr. Attilio Citrino, who also serves as data controller.

Its product portfolio is organized across two core lines plus a COVID-19 product line. The Medical Instrumentation line includes the IR-Force infrared spectrometer family (Series 200, 300, 500, 600) for C13 Urea Breath Test (UBT) analysis and the Lactotest 102 and 202 H2 breath test monitors that use electrochemical hydrogen sensors with optional methane (CH4) and carbon dioxide (CO2) detection via infrared analyzers. The Medical Diagnostic line comprises consumable kits: Citredici (C13 UBT), LactoBreath and GlucoBreath (H2 breath tests for lactose intolerance and SIBO), the BIO Fast HD ultra-rapid urease test for H. pylori biopsy detection using bromothymol blue, and the Helic Kit HPSA fecal antigen immunochromatographic rapid test. The COVID-19 line adds TAYHAMN FFP2 masks and SARS-CoV-2 rapid antigen (~97.67% reliability) and serological (~99.1% reliability) tests. Instruments are paired with PDI (Patient Data Interface) software for workflow integration.

Revenue is generated through one-time hardware sales of medical instruments plus recurring sales of consumable diagnostic kits. Pricing is not publicly disclosed and is handled through gated contact and registration forms. Distribution combines an internal field sales force with regional external sales agents in Italy (active recruitment across Piemonte, Liguria, and Emilia Romagna), broader European export activity, and, as of April 2024, an exclusive channel partnership with ITC Farma Srl covering the Breath Test sector. The company operates with approximately 25 professional employees and runs the Richen Group Open Competition research program in conjunction with the European Helicobacter & Microbiota Study Group (EHMSG), where it has maintained sponsorship since 2015.

Short descriptiontext

Richen Europe is an Italian pharmaceutical subsidiary of the Richen Medical Science Group that designs, manufactures, and distributes gastroenterology diagnostic instruments and consumables, including infrared spectrometers, H2 breath monitors, and H. pylori rapid tests, for hospitals and laboratories across Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTrezzano Sul Naviglio, Italy
HQ citystring
Trezzano Sul Naviglio
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gastroenterology diagnostics, breath test devices, medical instrumentation, helicobacter pylori testing, rapid diagnostic tests
Industry1 code
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Gastroenterology Medical Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Diagnostic Products
TypeOne Time License
Description

Richen Europe manufactures and sells medical diagnostic products including C13 Breath Test kits (Citredici), H2 Breath Test kits (LactoBreath, GlucoBreath), rapid tests (Helic Kit HPSA, BIO Fast HD), and COVID-19 diagnostic products. These are sold to hospitals, laboratories, and clinics across Europe.

richeneurope.eu
2Medical Instrumentation
TypeHardware Sales
Description

Sale of medical instruments including infrared spectrometers (IR-Force series) and H2 breath test monitors (Lactotest 102, Lactotest 202). Products are sold with associated software (PDI - Patient Data Interface) for data management and hospital system integration.

richeneurope.eu
3COVID-19 Products
TypeHardware Sales
Description

Sale of FFP2 masks (TAYHAMN brand) and SARS-CoV-2 rapid tests during the pandemic period.

richeneurope.eu
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Richen Medical Science Group
Description

Parent group encompassing Richen Europe and Beijing Richen Force Science & Technology Co, Ltd

richeneurope.eu
Core offering1 text field

Richen Europe manufactures and sells medical diagnostic kits and medical instruments focused on the gastroenterology field. Its portfolio covers C13 Urea Breath Test kits and infrared spectrometers, H2 Breath Test kits and Lactotest hydrogen/methane monitors for lactose intolerance and SIBO diagnosis, immunochromatographic rapid tests for H. pylori and SARS-CoV-2 detection, an ultra-rapid urease test (BIO Fast HD), and a line of COVID-19 products (FFP2 masks, rapid antigen and serological tests). The products are sold to hospitals, clinical laboratories, gastroenterology departments, and medical distributors across European markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • BIO Fast HD urease test achieves 100% specificity and 100% sensitivity for high-moderate bacterial count after 5 minutes
+2 more records
Product overview1 text field

Richen Europe offers a comprehensive portfolio of medical diagnostic products and medical instrumentation focused on gastroenterology, comprising two main product lines. The Medical Instrumentation line includes the Infrared Spectrometer series (200, 300, 500, 600) for C13 Urea Breath Test analysis using infrared technology, and the Lactotest H2 Breath Test monitors (102, 202) featuring electrochemical sensors for hydrogen, methane, and carbon dioxide detection. The Medical Diagnostic line comprises diagnostic kits including Citredici Urea Breath Test KIT, LactoBreath and GlucoBreath H2 Breath Test kits, BIO Fast HD rapid urease test, and Helic Kit HPSA rapid antigen test for Helicobacter pylori detection. Additionally, the company offers Covid-19 products including FFP2 masks, rapid antigen tests, and rapid serological tests for IgM/IgG antibodies. The portfolio is designed for use in gastroenterology practices, hospitals, and diagnostic laboratories.

Product and service14 records
1Citredici Urea Breath Test KIT
CategoryMedical Diagnostic
Description

Urea Breath Test kit for C13 breath test diagnosis used for the non-invasive detection of Helicobacter pylori infection; intended for hospitals, clinical laboratories, and gastroenterology departments.

2LactoBreath
CategoryMedical Diagnostic
Description

H2 Breath Test kit for diagnosis of lactose malabsorption or intolerance; includes lactose substrate and breath collection bags for use by clinical laboratories and gastroenterology departments.

3GlucoBreath
CategoryMedical Diagnostic
Description

H2 Breath Test kit for determination of bacterial intestinal contamination (SIBO diagnosis); includes glucose substrate and breath collection bags for clinical laboratories and gastroenterology departments.

4BIO Fast HD
CategoryMedical Diagnostic
Description

Ultra-rapid urease test for research and determination of Helicobacter pylori bacterial count during gastroscopy; uses bromothymol blue indicator for pH-based color change detection with 100% specificity and 100% sensitivity for high-moderate bacterial count after 5 minutes, retaining sensitivity under PPI therapy.

5Helic Kit - HPSA
CategoryMedical Diagnostic
Description

Immunochromatographic rapid test card for qualitative determination of Helicobacter pylori antigen in human fecal samples, providing non-invasive screening with high precision for hospitals and laboratories.

6Lactotest 102
CategoryMedical Instrumentation
Description

Hydrogen Breath Test monitor for rapid and reliable diagnosis of gastrointestinal disorders; features an electrochemical H2 sensor with thermal compensation, weekly calibration, and PDI software integration for hospital information system connectivity.

7Lactotest 202
CategoryMedical Instrumentation
Description

Hydrogen, methane, and carbon dioxide Breath Test monitor available in Control (H2+CO2) and Xtend (H2+CO2+CH4) variants; uses an electrochemical H2 sensor and infrared analyzers for CH4 and CO2 detection in gastroenterology diagnostics.

8Infrared Spectrometer Series 200
CategoryMedical Instrumentation
Description

Infrared spectrometer instrument for C13 Urea Breath Test analysis; entry-level compact analyzer used by clinical laboratories and gastroenterology departments for H. pylori detection.

9Infrared Spectrometer Series 300
CategoryMedical Instrumentation
Description

Infrared spectrometer instrument for C13 Urea Breath Test analysis; mid-range analyzer for clinical laboratories performing H. pylori diagnostics.

10Infrared Spectrometer Series 500
CategoryMedical Instrumentation
Description

Integrated infrared system for C13 Urea Breath Test analysis; fully integrated analyzer for high-volume clinical laboratory use in H. pylori detection workflows.

11Infrared Spectrometer Series 600
CategoryMedical Instrumentation
Description

Infrared spectrometer for C13 Urea Breath Test analysis; high-end analyzer in the IR-Force line used in clinical laboratories for H. pylori diagnostics.

12FFP2 Mask (TAYHAMN)
CategoryCovid-19 Product
Description

Single-use FFP2 protective mask without valve, featuring conformable nose clip and ear loops, compliant with EN149-2001+A1-2009; supplied in packs of 50 for healthcare facilities.

13SARS-COV-2 Rapid Antigen Test
CategoryCovid-19 Product
Description

Rapid antigen test using nasopharyngeal, nasal, or oral-faryngeal swab for direct detection of SARS-CoV-2 virus antigens; results in 10–60 minutes with approximately 97.67% reliability for healthcare providers.

14SARS-COV-2 Rapid Serological Test
CategoryCovid-19 Product
Description

Rapid serological test for detection of IgM/IgG antibodies against SARS-CoV-2 using immunochromatography on capillary blood samples; results in 10 minutes with approximately 99.1% reliability for healthcare providers.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1European Helicobacter & Microbiota Study Group (EHMSG)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-12
Description

Richen Europe participated as Industry Partner at the 37th EHMSG Workshop in Porto, Portugal, September 2024. The workshop is part of United European Gastroenterology.

richeneurope.eu
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-04-03
Description

Exclusive concession agreement signed with ITC Farma Srl in April 2024 for the Breath Test sector. The partnership combines Richen Europe's experience in breath test technology with ITC Farma's research and market expertise, marking a new challenge in the Breath Test sector. Announced at the 30th FISMAD Congress in Rome.

3SAIL in Bhutan
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Partnership supporting H. pylori eradication efforts in Bhutan, where infection rates reach 90% compared to 50% global average. The partnership aims to save lives from gastric cancer through H. pylori eradication, supporting the SAIL (Stool-based Antigens for Infant and Leptospirosis?) initiative.

richeneurope.eu
4European Helicobacter & Microbiota Study Group (EHMSG)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Since 2015, Richen Group has been supporting EHMSG as Platinum Sponsor (some sources indicate Gold Sponsor status). EHMSG is a multidisciplinary group founded in 1987, composed of representatives from most EU countries, organizing annual workshops on Helicobacter and microbiota research. Richen also runs research competitions (Open Competitions) for early-career researchers in partnership with EHMSG.

richeneurope.eu
5Beijing Richen Force Science & Technology Co, Ltd
Strategic tierCoreTypeTechnology or Integration
Description

Parent company and core technology partner within the Richen Medical Science Group. Part of the Richen Group structure, providing technological and manufacturing capabilities for the European subsidiary.

richeneurope.eu
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Finnish diagnostics company specializing in H. pylori and gastrointestinal diagnostics, including the GastroPanel blood-test panel and UBT products. Directly competes with Richen Europe in the gastroenterology diagnostic market across European hospital and lab channels.

TypeBroad incumbent
Description

Major European diagnostics manufacturer (now under Revvity) producing immunoassay reagents and automated analyzer systems for infectious disease and gastroenterology, including H. pylori serology. Larger-scale incumbent whose automated immunoassay platforms compete with Richen's specialized breath-test workflow.

TypeDirect peer
Description

US-based specialty GI diagnostics company offering hydrogen/methane breath testing for SIBO, IMO and lactose intolerance - directly comparable to Richen Europe's Lactotest H2/CH4/CO2 breath-test platform and GlucoBreath/LactoBreath kits. Both target the same gastroenterology use cases with non-invasive breath-based diagnostics.

4Alfa Wassermann
TypeRegional player
Description

Italian pharmaceutical and diagnostics company headquartered near Bologna, with divisions covering clinical chemistry, gastroenterology and hospital diagnostics. Regional European peer with comparable geography (Italy) and overlapping hospital lab customer base, though broader in therapeutic areas than Richen Europe's GI-only focus.

TypeBroad incumbent
Description

European specialty pharmaceutical company with a strong gastroenterology franchise (Aemcolo/ rifamycin, GI delivery technologies, and diagnostic devices). Comparable in its GI-specialist commercial focus but materially larger and publicly listed, with broader portfolio and balance sheet.

TypeBroad incumbent
Description

US-headquartered diagnostics company (now part of Revvity) with a leading gastroenterology product line including H. pylori stool antigen tests, Premier UBT platform, and C. difficile assays. Overlaps with Richen Europe's UBT and H. pylori antigen test portfolio but at much larger scale and global footprint.

TypeDirect peer
Description

French privately-held pharmaceutical company with a gastroenterology-focused portfolio including urea breath test (Kibion Dynamic) products. Directly comparable to Richen Europe as a specialty GI pharma and diagnostics player with European distribution.

TypeBroad incumbent
Description

Japanese pharmaceutical group with gastroenterology and H. pylori eradication therapy franchise (e.g., Pylera, vonoprazan-based regimens). Larger incumbent operating in the same downstream H. pylori care pathway that Richen Europe's diagnostic products feed into.

9Abbott Diagnostics
TypeBroad incumbent
Description

Global IVD leader with H. pylori serology and breath-test products (formerly Axis-Shield UBT) and broad hospital lab menu. Represents the large multinational competitor set that Richen Europe is differentiated against on specialty GI focus and clinical workflow integration.

TypeEmerging player
Description

Spanish biotech focused on microbiome-based diagnostics and probiotics, with H. pylori and gut-health products. Comparable emerging European player addressing overlapping gastroenterology/microbiota use cases (e.g., H. pylori eradication, SIBO), but at smaller scale and more research-stage.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Richen Europe

Gastroenterology Medical Diagnosticsricheneurope.eu

Richen Europe is an Italian pharmaceutical subsidiary of the Richen Medical Science Group that designs, manufactures, and distributes gastroenterology diagnostic instruments and consumables, including infrared spectrometers, H2 breath monitors, and H. pylori rapid tests, for hospitals and laboratories across Europe.

What Richen Europe does

Richen Europe S.r.l. is an Italian pharmaceutical company founded in 2014 and headquartered in Trezzano Sul Naviglio (Milan), operating as the European subsidiary of the Richen Medical Science Group, whose Chinese parent is Beijing Richen Force Science & Technology Co., Ltd. The company manufactures medical diagnostic products and medical instrumentation focused on gastroenterology, serving hospitals, clinical laboratories, and gastroenterology departments across European markets with a stated base of approximately 285 international clients and 13 gastroenterology products. The group is led by Managing Director Dr. Attilio Citrino, who also serves as data controller.

Its product portfolio is organized across two core lines plus a COVID-19 product line. The Medical Instrumentation line includes the IR-Force infrared spectrometer family (Series 200, 300, 500, 600) for C13 Urea Breath Test (UBT) analysis and the Lactotest 102 and 202 H2 breath test monitors that use electrochemical hydrogen sensors with optional methane (CH4) and carbon dioxide (CO2) detection via infrared analyzers. The Medical Diagnostic line comprises consumable kits: Citredici (C13 UBT), LactoBreath and GlucoBreath (H2 breath tests for lactose intolerance and SIBO), the BIO Fast HD ultra-rapid urease test for H. pylori biopsy detection using bromothymol blue, and the Helic Kit HPSA fecal antigen immunochromatographic rapid test. The COVID-19 line adds TAYHAMN FFP2 masks and SARS-CoV-2 rapid antigen (~97.67% reliability) and serological (~99.1% reliability) tests. Instruments are paired with PDI (Patient Data Interface) software for workflow integration.

Revenue is generated through one-time hardware sales of medical instruments plus recurring sales of consumable diagnostic kits. Pricing is not publicly disclosed and is handled through gated contact and registration forms. Distribution combines an internal field sales force with regional external sales agents in Italy (active recruitment across Piemonte, Liguria, and Emilia Romagna), broader European export activity, and, as of April 2024, an exclusive channel partnership with ITC Farma Srl covering the Breath Test sector. The company operates with approximately 25 professional employees and runs the Richen Group Open Competition research program in conjunction with the European Helicobacter & Microbiota Study Group (EHMSG), where it has maintained sponsorship since 2015.

Richen Europe firmographics

Firmographics
Name
Richen Europe
Legal name
Richen Europe S.r.l.
Website
https://richeneurope.eu
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Richen Europe is an Italian pharmaceutical subsidiary of the Richen Medical Science Group that designs, manufactures, and distributes gastroenterology diagnostic instruments and consumables, including infrared spectrometers, H2 breath monitors, and H. pylori rapid tests, for hospitals and laboratories across Europe.
Ownership category
akta.pro rank

Richen Europe industry classification

Industry
Product category
Gastroenterology Medical Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Keywords

  • Gastroenterology diagnostics
  • Breath test devices
  • Medical instrumentation
  • Helicobacter pylori testing
  • Rapid diagnostic tests

Where Richen Europe is headquartered

Location

Headquarters

HQ city
Trezzano Sul Naviglio
HQ country
Italy
HQ region
Europe

Offices2 records

Markets served

Richen Europe business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Medical Diagnostic Products: Richen Europe manufactures and sells medical diagnostic products including C13 Breath Test kits (Citredici), H2 Breath Test kits (LactoBreath, GlucoBreath), rapid tests (Helic Kit HPSA, BIO Fast HD), and COVID-19 diagnostic products. These are sold to hospitals, laboratories, and clinics across Europe.
  2. Medical Instrumentation: Sale of medical instruments including infrared spectrometers (IR-Force series) and H2 breath test monitors (Lactotest 102, Lactotest 202). Products are sold with associated software (PDI - Patient Data Interface) for data management and hospital system integration.
  3. COVID-19 Products: Sale of FFP2 masks (TAYHAMN brand) and SARS-CoV-2 rapid tests during the pandemic period.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Richen Europe product offering

Product offering

Core offering

Richen Europe manufactures and sells medical diagnostic kits and medical instruments focused on the gastroenterology field. Its portfolio covers C13 Urea Breath Test kits and infrared spectrometers, H2 Breath Test kits and Lactotest hydrogen/methane monitors for lactose intolerance and SIBO diagnosis, immunochromatographic rapid tests for H. pylori and SARS-CoV-2 detection, an ultra-rapid urease test (BIO Fast HD), and a line of COVID-19 products (FFP2 masks, rapid antigen and serological tests). The products are sold to hospitals, clinical laboratories, gastroenterology departments, and medical distributors across European markets.

Product overview

Richen Europe offers a comprehensive portfolio of medical diagnostic products and medical instrumentation focused on gastroenterology, comprising two main product lines. The Medical Instrumentation line includes the Infrared Spectrometer series (200, 300, 500, 600) for C13 Urea Breath Test analysis using infrared technology, and the Lactotest H2 Breath Test monitors (102, 202) featuring electrochemical sensors for hydrogen, methane, and carbon dioxide detection. The Medical Diagnostic line comprises diagnostic kits including Citredici Urea Breath Test KIT, LactoBreath and GlucoBreath H2 Breath Test kits, BIO Fast HD rapid urease test, and Helic Kit HPSA rapid antigen test for Helicobacter pylori detection. Additionally, the company offers Covid-19 products including FFP2 masks, rapid antigen tests, and rapid serological tests for IgM/IgG antibodies. The portfolio is designed for use in gastroenterology practices, hospitals, and diagnostic laboratories.

Differentiator

Problem solved

Functional benefit

Brands

  • Richen Medical Science Group: Parent group encompassing Richen Europe and Beijing Richen Force Science & Technology Co, Ltd

Products and services

  • Citredici Urea Breath Test KIT Urea Breath Test kit for C13 breath test diagnosis used for the non-invasive detection of Helicobacter pylori infection; intended for hospitals, clinical laboratories, and gastroenterology departments.
  • LactoBreath H2 Breath Test kit for diagnosis of lactose malabsorption or intolerance; includes lactose substrate and breath collection bags for use by clinical laboratories and gastroenterology departments.
  • GlucoBreath H2 Breath Test kit for determination of bacterial intestinal contamination (SIBO diagnosis); includes glucose substrate and breath collection bags for clinical laboratories and gastroenterology departments.
  • BIO Fast HD Ultra-rapid urease test for research and determination of Helicobacter pylori bacterial count during gastroscopy; uses bromothymol blue indicator for pH-based color change detection with 100% specificity and 100% sensitivity for high-moderate bacterial count after 5 minutes, retaining sensitivity under PPI therapy.
  • Helic Kit - HPSA Immunochromatographic rapid test card for qualitative determination of Helicobacter pylori antigen in human fecal samples, providing non-invasive screening with high precision for hospitals and laboratories.
  • Lactotest 102 Hydrogen Breath Test monitor for rapid and reliable diagnosis of gastrointestinal disorders; features an electrochemical H2 sensor with thermal compensation, weekly calibration, and PDI software integration for hospital information system connectivity.
  • Lactotest 202 Hydrogen, methane, and carbon dioxide Breath Test monitor available in Control (H2+CO2) and Xtend (H2+CO2+CH4) variants; uses an electrochemical H2 sensor and infrared analyzers for CH4 and CO2 detection in gastroenterology diagnostics.
  • Infrared Spectrometer Series 200 Infrared spectrometer instrument for C13 Urea Breath Test analysis; entry-level compact analyzer used by clinical laboratories and gastroenterology departments for H. pylori detection.
  • Infrared Spectrometer Series 300 Infrared spectrometer instrument for C13 Urea Breath Test analysis; mid-range analyzer for clinical laboratories performing H. pylori diagnostics.
  • Infrared Spectrometer Series 500 Integrated infrared system for C13 Urea Breath Test analysis; fully integrated analyzer for high-volume clinical laboratory use in H. pylori detection workflows.
  • Infrared Spectrometer Series 600 Infrared spectrometer for C13 Urea Breath Test analysis; high-end analyzer in the IR-Force line used in clinical laboratories for H. pylori diagnostics.
  • FFP2 Mask (TAYHAMN) Single-use FFP2 protective mask without valve, featuring conformable nose clip and ear loops, compliant with EN149-2001+A1-2009; supplied in packs of 50 for healthcare facilities.
  • SARS-COV-2 Rapid Antigen Test Rapid antigen test using nasopharyngeal, nasal, or oral-faryngeal swab for direct detection of SARS-CoV-2 virus antigens; results in 10–60 minutes with approximately 97.67% reliability for healthcare providers.
  • SARS-COV-2 Rapid Serological Test Rapid serological test for detection of IgM/IgG antibodies against SARS-CoV-2 using immunochromatography on capillary blood samples; results in 10 minutes with approximately 99.1% reliability for healthcare providers.

Quantifiable outcome

  • BIO Fast HD urease test achieves 100% specificity and 100% sensitivity for high-moderate bacterial count after 5 minutes
  • +2 more outcomes

Companies that use Richen Europe

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Richen Europe technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Richen Europe partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • European Helicobacter & Microbiota Study Group (EHMSG)coreStrategic or Co-development Partner · 12 September 2024Richen Europe participated as Industry Partner at the 37th EHMSG Workshop in Porto, Portugal, September 2024. The workshop is part of United European Gastroenterology.
  • ITC Farma SrlcoreChannel Partner/ Reseller/ Distributor · 3 April 2024Exclusive concession agreement signed with ITC Farma Srl in April 2024 for the Breath Test sector. The partnership combines Richen Europe's experience in breath test technology with ITC Farma's research and market expertise, marking a new challenge in the Breath Test sector. Announced at the 30th FISMAD Congress in Rome.
  • SAIL in BhutanminorStrategic or Co-development Partner · 1 January 2018Partnership supporting H. pylori eradication efforts in Bhutan, where infection rates reach 90% compared to 50% global average. The partnership aims to save lives from gastric cancer through H. pylori eradication, supporting the SAIL (Stool-based Antigens for Infant and Leptospirosis?) initiative.
  • European Helicobacter & Microbiota Study Group (EHMSG)coreStrategic or Co-development Partner · 1 January 2015Since 2015, Richen Group has been supporting EHMSG as Platinum Sponsor (some sources indicate Gold Sponsor status). EHMSG is a multidisciplinary group founded in 1987, composed of representatives from most EU countries, organizing annual workshops on Helicobacter and microbiota research. Richen also runs research competitions (Open Competitions) for early-career researchers in partnership with EHMSG.
  • Beijing Richen Force Science & Technology Co, LtdcoreTechnology or IntegrationParent company and core technology partner within the Richen Medical Science Group. Part of the Richen Group structure, providing technological and manufacturing capabilities for the European subsidiary.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Richen Europe competitors and assessment

Company assessment

Direct peers

  • Biohit Oyj: Finnish diagnostics company specializing in H. pylori and gastrointestinal diagnostics, including the GastroPanel blood-test panel and UBT products. Directly competes with Richen Europe in the gastroenterology diagnostic market across European hospital and lab channels.
  • Commonwealth Diagnostics & Sciences (Gemelli Biotech): US-based specialty GI diagnostics company offering hydrogen/methane breath testing for SIBO, IMO and lactose intolerance - directly comparable to Richen Europe's Lactotest H2/CH4/CO2 breath-test platform and GlucoBreath/LactoBreath kits. Both target the same gastroenterology use cases with non-invasive breath-based diagnostics.
  • Mayoly Spindler: French privately-held pharmaceutical company with a gastroenterology-focused portfolio including urea breath test (Kibion Dynamic) products. Directly comparable to Richen Europe as a specialty GI pharma and diagnostics player with European distribution.

Broad incumbents

  • EUROIMMUN (Revvity/PerkinElmer): Major European diagnostics manufacturer (now under Revvity) producing immunoassay reagents and automated analyzer systems for infectious disease and gastroenterology, including H. pylori serology. Larger-scale incumbent whose automated immunoassay platforms compete with Richen's specialized breath-test workflow.
  • Cosmo Pharmaceuticals: European specialty pharmaceutical company with a strong gastroenterology franchise (Aemcolo/ rifamycin, GI delivery technologies, and diagnostic devices). Comparable in its GI-specialist commercial focus but materially larger and publicly listed, with broader portfolio and balance sheet.
  • Meridian Bioscience (Revvity): US-headquartered diagnostics company (now part of Revvity) with a leading gastroenterology product line including H. pylori stool antigen tests, Premier UBT platform, and C. difficile assays. Overlaps with Richen Europe's UBT and H. pylori antigen test portfolio but at much larger scale and global footprint.
  • Otsuka Holdings (Otsuka Pharmaceutical): Japanese pharmaceutical group with gastroenterology and H. pylori eradication therapy franchise (e.g., Pylera, vonoprazan-based regimens). Larger incumbent operating in the same downstream H. pylori care pathway that Richen Europe's diagnostic products feed into.
  • Abbott Diagnostics: Global IVD leader with H. pylori serology and breath-test products (formerly Axis-Shield UBT) and broad hospital lab menu. Represents the large multinational competitor set that Richen Europe is differentiated against on specialty GI focus and clinical workflow integration.

Regional players

  • Alfa Wassermann: Italian pharmaceutical and diagnostics company headquartered near Bologna, with divisions covering clinical chemistry, gastroenterology and hospital diagnostics. Regional European peer with comparable geography (Italy) and overlapping hospital lab customer base, though broader in therapeutic areas than Richen Europe's GI-only focus.

Emerging players

  • AB Biotics: Spanish biotech focused on microbiome-based diagnostics and probiotics, with H. pylori and gut-health products. Comparable emerging European player addressing overlapping gastroenterology/microbiota use cases (e.g., H. pylori eradication, SIBO), but at smaller scale and more research-stage.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Richen Europe social profiles

Digital presence

Richen Europe financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Richen Europe leadership team

Management profile

Number of profiles

Profiles1 record

Richen Europe funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Richen Europe M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Richen Europe

What does Richen Europe do?

Richen Europe manufactures and sells medical diagnostic kits and medical instruments focused on the gastroenterology field. Its portfolio covers C13 Urea Breath Test kits and infrared spectrometers, H2 Breath Test kits and Lactotest hydrogen/methane monitors for lactose intolerance and SIBO diagnosis, immunochromatographic rapid tests for H. pylori and SARS-CoV-2 detection, an ultra-rapid urease test (BIO Fast HD), and a line of COVID-19 products (FFP2 masks, rapid antigen and serological tests). The products are sold to hospitals, clinical laboratories, gastroenterology departments, and medical distributors across European markets.

Is Richen Europe a public or private company?

Richen Europe is a private company. It is classified as corporate owned and is currently operating.

When was Richen Europe founded?

Richen Europe was founded in 2014. It employs 11 to 50 people.

Where is Richen Europe based?

Richen Europe is headquartered in Trezzano Sul Naviglio, Italy, in the Europe region.

How does Richen Europe make money?

Three revenue lines are on record. Medical Diagnostic Products are the primary driver. The others are medical Instrumentation and COVID-19 Products.

Who are Richen Europe's main competitors?

Direct peers on record are Biohit Oyj, Commonwealth Diagnostics & Sciences (Gemelli Biotech) and Mayoly Spindler. Broad incumbents are EUROIMMUN (Revvity/PerkinElmer), Cosmo Pharmaceuticals, Meridian Bioscience (Revvity), Otsuka Holdings (Otsuka Pharmaceutical) and Abbott Diagnostics. Alfa Wassermann is listed as a regional player. AB Biotics is listed as an emerging player.

Does Richen Europe have an API?

No public API is recorded for Richen Europe.

What industry is Richen Europe in?

Richen Europe's product category is Gastroenterology Medical Diagnostics. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales